Gunne L M, Häggström J E, Sjöquist B
Nature. 1984;309(5966):347-9. doi: 10.1038/309347a0.
The movement disorder tardive dyskinesia is a serious side effect of the long-term treatment of schizophrenia with neuroleptic drugs. Similar symptoms to those of tardive dyskinesia have been observed in Cebus apella monkeys following long-term treatment with neuroleptic drugs, and these monkeys may therefore be a useful animal model of tardive dyskinesia. Motor defects have persisted in these dyskinetic monkeys for periods of 1-6 yr after the cessation of neuroleptic treatment. We report here that in three regions of the brains of dyskinetic monkeys (substantia nigra, medial globus pallidus and subthalamic nucleus) glutamate decarboxylase activities and gamma-aminobutyric acid (GABA) levels are reduced relative to control monkeys that had been treated with neuroleptics but which showed none of the symptoms of tardive dyskinesia. These results suggest that alterations in the GABA neurone system are involved in neuroleptic drug-induced tardive dyskinesia.
运动障碍迟发性运动障碍是用抗精神病药物长期治疗精神分裂症的一种严重副作用。在用抗精神病药物长期治疗后的僧帽猴中观察到了与迟发性运动障碍相似的症状,因此这些猴子可能是迟发性运动障碍的一种有用动物模型。在停止抗精神病药物治疗后,这些患有运动障碍的猴子的运动缺陷持续了1至6年。我们在此报告,与接受过抗精神病药物治疗但未出现迟发性运动障碍症状的对照猴子相比,患有运动障碍的猴子大脑的三个区域(黑质、苍白球内侧部和丘脑底核)的谷氨酸脱羧酶活性和γ-氨基丁酸(GABA)水平降低。这些结果表明,GABA神经元系统的改变与抗精神病药物诱发的迟发性运动障碍有关。